Skip to main content
. 2016 Aug 27;23(3):217–230. doi: 10.1007/s40292-016-0155-2

Fig. 4.

Fig. 4

The ODYSSEY clinical trial program. CV cardiovascular, FH familial hypercholesterolemia, HC hypercholesterolemia, HeFH heterozygous familial hypercholesterolemia, LDL-C low density lipoprotein cholesterol, LMT lipid modifying therapy. Asterisk For the ODYSSEY COMBO II other LMT not allowed at entry